Beranda › Kanker Ginjal (Karsinoma Sel Renal) › Minnesota › Rochester
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di Rochester, MN
14 studi untuk Kanker Ginjal (Karsinoma Sel Renal) mencari peserta di lokasi sekitar Rochester (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Menerima pesertaFase 1
- Mayo Clinic Rochester, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #68, Rochester
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Menerima pesertaFase 2
- Mayo Clinic in Rochester, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- Mayo Clinic Rochester, Rochester
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Menerima pesertaFase 2
- Mayo Clinic in Rochester, Rochester
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Menerima pesertaFase 1/2
- Mayo Clinic Hospital, Methodist Campus, Research Pharmacy, Rochester
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- Mayo Clinic (Rochester), Rochester
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- Xencor Investigative Site, Rochester
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Menerima pesertaFase 1/2
- Mayo Clinic, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Menerima pesertaFase 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 2
- Mayo Clinic in Rochester, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Menerima pesertaStudi observasional
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Menerima pesertaFase 1/2
- Mayo Clinic in Minnesota, Rochester
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di kota lain
- Houston, TX35 studi
- New York City, NY27 studi
- Dallas, TX23 studi
- Nashville, TN23 studi
- St. Louis, MO23 studi
- Los Angeles, CA20 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Jacksonville, FL14 studi
Studi lain di Rochester
- Kanker Payudara42 studi
- Kanker Paru Non-Sel Kecil37 studi
- Kanker Metastatik31 studi
- Kanker (semua jenis)30 studi
- Kanker Ovarium29 studi
- Kanker Kolorektal29 studi
- Mieloma Multipel24 studi
- Gagal Jantung22 studi
- Kanker Prostat22 studi
- Kanker Pankreas22 studi
- Kanker Endometrium20 studi
- Kanker Paru20 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.